Scope Fluidics S.A.

Warsaw Stock Exchange SCP.WA

Scope Fluidics S.A. EBITDA Margin for the year ending December 31, 2023: -3,342.44%

Scope Fluidics S.A. EBITDA Margin is -3,342.44% for the year ending December 31, 2023, a -103.41% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Scope Fluidics S.A. EBITDA Margin for the year ending December 31, 2022 was 98,152.97%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Warsaw Stock Exchange: SCP.WA

Scope Fluidics S.A.

CEO Mr. Piotr Garstecki
IPO Date Aug. 1, 2017
Location Poland
Headquarters 9th floor
Employees 40
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.

Similar companies

COG.WA

Cognor Holding S.A.

USD 1.64

0.89%

BMC.WA

Bumech S.A.

USD 2.85

2.48%

StockViz Staff

January 15, 2025

Any question? Send us an email